Logo image
Back
High‐Dose Cyclophosphamide in the Treatment of Multiple Sclerosis
Journal article   Open access   Peer reviewed

High‐Dose Cyclophosphamide in the Treatment of Multiple Sclerosis

Robert Jay Schwartzman, Nicole Simpkins, Guillermo M. Alexander, Erin Reichenberger, Kristine Ward, Noah Lindenberg, David Topolsky and Pam Crilley
CNS neuroscience & therapeutics, v 15(2)
23 Feb 2009
DOI: https://doi.org/10.1111/j.1755-5949.2008.00072.x
PMID: 19243391
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1111/j.1755-5949.2008.00072.xView
Published, Version of Record (VoR)Open Access (License Unspecified),  Open

Abstract

Drug Focus
High dose cyclophosphamide (HDC) has been successfully used for the treatment of a variety of autoimmune diseases. In this study, we sought to determine whether the use of high dose cyclophosphamide provided stabilization of relapsing remitting MS (RRMS), secondary progressive MS (SPMS), or primary progressive MS (PPMS). The parameters evaluated were EDSS scores, lesion load and brain volumes by MRI and frequency of relapses. Twenty‐three patients underwent immunoablative therapy with HDC and were followed for 3.5 years. Nine were relapsing remitting (RRMS), 11 secondary progressive (SPMS), and 3 primary progressive (PPMS). Four of 9 RRMS have had no clinical progression up to 3.5 years following treatment. Three of 9 patients maintained a normal neurologic examination with improved EDSS scores. Seven of the nine RRMS patients had reduction in flare frequency which was maintained for 3.5 years following treatment or no immunomodulating agents. Subgroup analysis in the RRMS patients of lesion load and brain parenchymal volume revealed a favorable trend in these parameters which did not reach statistical significance. The treatment was generally ineffective for SPMS and failed in the 2 PPMS patients. HDC was well tolerated, demonstrated a good safety profile and had minimal adverse effects. These results along with previous reports suggest that early use of HDC therapy in RRMS is promising.

Metrics

14 Record Views
16 citations in Web of Science
22 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Neurosciences
Pharmacology & Pharmacy
Logo image